COMMUNIQUÉS West-GlobeNewswire

Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented Dyspareunia Drug Candidate and Other Intellectual Property
07/02/2019
Mayfield, a women’s health focused drug development company, intends to seek FDA approval for MAY-44 Dyspareunia treatment drug candidate via the 505(b)(2) approval pathway SAN DIEGO, Feb. 07, 2019 (GLOBE NEWSWIRE) -- [...]
Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy
07/02/2019
- Company expediting planned dose escalation activities - - Low levels of SGT-001 microdystrophin protein detected at the starting dose - - Conference call to be held at 8:30 a.m. ET today - CAMBRIDGE, Mass., Feb. 07, [...]
LHC Group Announces Fourth Quarter 2018 Earnings Release and Conference Call Dates
07/02/2019
LAFAYETTE, La., Feb. 07, 2019 (GLOBE NEWSWIRE) -- LHC Group, Inc . (NASDAQ: LHCG) today announced details for the release of its results for the fourth quarter and year ended December 31, 2018. LHC Group plans to issue [...]
C-RAD and XECAN announce strategic development and sales cooperation
07/02/2019
C-RAD and the US based company XECAN signed a partnership agreement to develop new products to advance patient positioning and resource management within radiation therapy. The development work will start immediately [...]
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2019 Financial Results on February 12, 2019
07/02/2019
Financials for Third Quarter Fiscal Year 2019 Ended December 31, 2018 will be released February 11, 2019 Northvale, NJ, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB: [...]
RavenQuest Issues Statement in Response to Health Canada Sales License Suspension at Bonify
07/02/2019
VANCOUVER, British Columbia, Feb. 07, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB, OTCQB: RVVQF, Frankfurt: 1IT) CEO, George Robinson, also acting President & CEO at [...]
CellaVision AB Year-end bulletin, Jan-Dec 2018
07/02/2019
CellaVision's best quarter ever with strong growth October 1 - December 31, 2018 · Net sales increased by 46% to SEK 111,0 million (76.1). · Organic growth increased to 44% (6) · Operating profit increased to SEK 35.8 [...]
Sanofi delivers 2018 business EPS growth of 5.1% at CER
07/02/2019
Paris, February 7, 2019 Sanofi delivers 2018 business EPS growth of 5.1% at CER Q4 2018 Change Change at CER 2018 Change Change at CER IFRS net sales reported €8,997m +3.5% +3.9% €34,463m -1.7% +2.5% IFRS net income [...]
Sanofi annonce une croissance du BNPA des activités 2018 de 5,1% à TCC
07/02/2019
Paris, le 7 février 2019 Sanofi annonce une croissance du BNPA des activités 2018 de 5,1% à TCC T4 2018 Variation Variation à TCC 2018 Variation Variation à TCC Chiffre d'affaires net IFRS publié €8 997m +3,5% +3,9% €34 [...]
ALK releases its annual report 2018
07/02/2019
Today, ALK’s ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) Board of Directors has considered and approved the 2018 annual report with the following highlights: 2018 saw strong progress for ALK’s new strategy, keeping ALK on [...]
Evotec and Galapagos enter into collaboration in the field of fibrosis
07/02/2019
Mechelen, Belgium, and Hamburg, Germany; 7 February 2019, 7.30 CET - Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809), and Galapagos NV (Euronext & NASDAQ: GLPG) today announced a global [...]
Basilea announces change in the Management Committee - Adesh Kaul appointed CFO
07/02/2019
Basel, February 7, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Board of Directors has appointed Adesh Kaul, currently Chief Corporate Development Officer and member of the Management Committee [...]
Fagron realized turnover growth of 14.5%; REBITDA increased to € 99.1 million
07/02/2019
Regulated information Nazareth (Belgium)/Rotterdam (the Netherlands), 7 February 2019 Organic turnover growth accelerated in the second half of the year Highlights - Financial Turnover amounted to € 471.7 million in [...]
Idorsia announces financial results for 2018 - outstanding progress made - four late stage assets advanced into Phase 3
07/02/2019
Allschwil, Switzerland - February 7, 2019 Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year 2018. Key Updates Advancing pipeline - four Phase 3 programs initiated Operational independence [...]
Precision Optics Corporation Schedules Second Quarter Conference Call
07/02/2019
GARDNER, Mass., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (OTCQB: PEYE) (the “Company”) today announced that it intends to release its financial results for the fiscal year 2019 second quarter [...]
RavenQuest Issues Statement in Response to Health Canada Sales License Suspension at Bonify
07/02/2019
VANCOUVER, British Columbia, Feb. 06, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB, OTCQB: RVVQF, Frankfurt: 1IT) CEO, George Robinson, also acting President & CEO at [...]
Hemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering
06/02/2019
OCALA, Fla., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical [...]
New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections
06/02/2019
Once-daily IV-to-oral NUZYRA safe and effective in adults with pneumonia and skin infections, demonstrating clinical activity against relevant pneumonia- and skin-associated drug resistant bacteria BOSTON, Feb. 06, 2019 [...]
LeMaitre Vascular Will Announce Fourth Quarter 2018 Earnings Results on February 19, 2019
06/02/2019
BURLINGTON, Mass., Feb. 06, 2019 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2018 financial results on Tuesday, February 19, 2019, after the market [...]

Pages